Somewhat Positive Press Coverage Somewhat Unlikely to Affect Haemonetics (HAE) Share Price

News articles about Haemonetics (NYSE:HAE) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Haemonetics earned a news impact score of 0.13 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 45.8963735326244 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Several research firms recently weighed in on HAE. Zacks Investment Research lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, November 20th. Morgan Stanley increased their price target on shares of Haemonetics from $43.00 to $51.00 and gave the company an “equal weight” rating in a research report on Thursday, November 9th. Craig Hallum restated a “hold” rating and set a $50.00 price target (up previously from $40.00) on shares of Haemonetics in a research report on Wednesday, November 8th. Finally, Barrington Research increased their price target on shares of Haemonetics from $48.00 to $57.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $53.33.

Haemonetics (HAE) traded down $0.06 on Friday, reaching $58.46. 132,743 shares of the company traded hands, compared to its average volume of 501,493. The company has a market capitalization of $3,080.00, a price-to-earnings ratio of 835.14, a P/E/G ratio of 4.40 and a beta of 0.99. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.51 and a current ratio of 2.17. Haemonetics has a one year low of $36.44 and a one year high of $58.99.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.07. The business had revenue of $225.40 million for the quarter, compared to the consensus estimate of $219.12 million. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The company’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.38 earnings per share. equities analysts predict that Haemonetics will post 1.7 EPS for the current year.

In other Haemonetics news, Director Susan Bartlett Foote sold 16,926 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $54.19, for a total transaction of $917,219.94. Following the sale, the director now directly owns 27,313 shares of the company’s stock, valued at $1,480,091.47. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Willaim P. Burke sold 13,193 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $54.04, for a total transaction of $712,949.72. Following the sale, the chief financial officer now directly owns 27,227 shares in the company, valued at $1,471,347.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,368 shares of company stock worth $2,602,393. Insiders own 1.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/24/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-haemonetics-hae-share-price.html.

About Haemonetics

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit